Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Metabolic · Dosing reference

HGH Fragment 176-191 dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyCPreclinical researchNone established
Full research pageCycle-length evidenceComparePrefer Amiravo on Google
Regulatory status
Not approved — research use only
Human amounts
None established in humans
Route studied
—
Frequency
Not established
Half-life
Not established
Evidence grade
Grade C · Preclinical research
Vial sizes on the market
Not recorded
Other forms seen
—

What HGH Fragment 176-191 is

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of human growth hormone, investigated in laboratory studies of lipid metabolism.

No receptor or defined signalling pathway has been established for hGH 176-191 in the sources read for this entry. The fragment comes from a structure-activity programme in which synthetic peptides corresponding to several overlapping C-terminal stretches of human growth hormone were tested to find which carried the hormone's metabolic effects 4. What the mapping work found Of the six fragments tested in rats,… How it works →

Key evidence

  • Ng and Bornstein, Am J Physiol · 1978 · Rats (normal)
    hGH 176-191 and three neighbouring fragments raised blood glucose transiently and plasma insulin more durably; fragments containing 178-191 reduced insulin sensitivity, while 179-191 and 180-191 were inert. 4
  • Wu and Ng, Biochem Mol Biol Int · 1993 · Rats
    The fragment was antilipogenic to a degree comparable with intact growth hormone, with no significant lipolytic effect detected - a result that cuts against a simple fat-burning account of this region of the hormone. 5
  • Ng et al., Horm Res · 2000 · Rats (obese Zucker)
    Body-weight gain was reduced relative to control and adipose lipolytic activity increased, without the adverse effect on insulin sensitivity seen with intact growth hormone. This concerns AOD-9604, not hGH 176-191. 6
All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered HGH Fragment 176-191. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for HGH Fragment 176-191.

Cycle-length evidence for HGH Fragment 176-191

HGH Fragment 176-191 draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength
2 · Water added
3 · Amount per draw
4 · Syringe
Your mix
10 mg + 2 mL water = 5 mg/mL
10 units holds 0.5 mg (500 mcg)
Draw toEnter an amount in step 3
0102030405060708090100
U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Watermg/mLDraw
0.5 mL20—
1 mL10—
1.5 mL6.667—
2 mL5—
2.5 mL4—
3 mL3.333—
5 mL2—

Supplies and handling

  • Lyophilized vial
    Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
  • Sterile diluent
    The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
  • Graduated syringes
    Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
  • Alcohol prep pads
    For wiping vial stoppers before each puncture.
  • Nitrile gloves
    Clean gloves for aseptic handling.
  • Sharps container
    Puncture-resistant container for used needles.
Step-by-step reconstitution guideStorage and transport accessories

Storage

General research-context handling only. Lyophilised peptide is normally kept cold, dry and protected from light, and reconstituted material is far less stable than the dry powder; cysteine-containing peptides are additionally sensitive to oxidation. Follow the storage temperature, retest date and handling guidance in the supplier's documentation for the specific lot. No preparation or handling instructions are given here.

  • Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
  • Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
  • Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent
The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed
Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles
Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution
This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed
Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status
The growth hormone fragment hGH 176-191 has no approved drug application in the United States; Drugs@FDA / openFDA searches for "176-191" and for "hGH fragment" return no records 1. It is named in the WADA 2026 Prohibited List, section S2.2.3 2.
United States (FDA)
Not approved. Drugs@FDA / openFDA queries for "176-191", "hGH fragment" and the related fragment "AOD-9604" return no matching applications 1.
Sport (WADA)
Prohibited at all times. Section S2.2.3, "Growth hormone (GH), its analogues and fragments including, but not limited to:", names "growth hormone fragments, e.g. AOD-9604 and hGH 176-191" 2. Class S2 substances are prohibited in- and out-of-competition and are non-Specified.

Status varies by country and changes over time. How we describe regulatory status.

HGH Fragment 176-191 compared with related compounds

CompoundStatusEvidenceHuman amountsHalf-life
HGH Fragment 176-191Not approved — research use onlyCNone established—
AOD-9604Not approved — research use onlyCNone established—
TesofensineInvestigationalBTrial dosesAbout 234 hours (M1 metabolite about 374
MazdutideApproved outside the USATrial doses150.9 to 403.5 hours (phase 1b in overwe
CagrilintideInvestigationalATrial doses159 to 195 hours (phase 1b, co-administe
SLU-PP-332Not approved — research use onlyCNone establishedUnknown in humans

Frequently asked questions

What doses of HGH Fragment 176-191 have been studied in humans?
None that establish an amount. HGH Fragment 176-191 is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.
Is there an established HGH Fragment 176-191 cycle length?
No. We found no human studies that report treatment duration for HGH Fragment 176-191.
How much bacteriostatic water should be added to a HGH Fragment 176-191 vial?
There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.
How many units is a given amount on an insulin syringe?
On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.
Is HGH Fragment 176-191 FDA-approved?
Not approved — research use only. The growth hormone fragment hGH 176-191 has no approved drug application in the United States; Drugs@FDA / openFDA searches for "176-191" and for "hGH fragment" return no records 1. It is named in the WADA 2026 Prohibited List, section S2.2.3 2.

References

  1. Drugs@FDA application data queried through openFDA for hGH fragment 176-191 and AOD-9604 (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  2. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
  3. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells Drug Des Devel Ther. 2022
  4. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone Am J Physiol. 1978
  5. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone Biochem Mol Biol Int. 1993
  6. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone Horm Res. 2000
  7. PubChem compound record for human growth hormone fragment 176-191 (CID 172966176) PubChem. 2026
  8. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis (describes AOD9604 as hGH 176-191 with an added N-terminal tyrosine and summarises the limited human evidence) Front Endocrinol (Lausanne). 2026

Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error